Having proven the concept of our platform across diverse cell types and cell behaviors, we have selected hematology and immunology as our first therapeutic areas (TA) to build out a diverse portfolio of Cellarity-initiated programs that leverage the strong scientific capabilities that we have developed.

To fulfill and accelerate the broad potential of our platform, we have partnered programs applying our disruptive approach to areas of strategic interest to partner companies. Our first example of this is our program addressing novel biologic insights in Metabolic Dysfunction-Associated Steatohepatitis (MASH) in partnership with Novo Nordisk.

Scroll sideways to view more